Vanda Pharmaceuticals (NASDAQ: VNDA)
Vanda Pharmaceuticals Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Vanda Pharmaceuticals Company Info
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
News & Analysis
Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today
A regulator's decision drained the market's enthusiasm for the company.
Why Vanda Pharmaceuticals Stock Is Skyrocketing Today
Future Pak wants Vanda, but Vanda doesn't want Future Pak.
Why Shares of Vanda Pharmaceuticals Are Dropping on Tuesday
The pharmaceutical company's stock hit another 52-week low.
Why Vanda Pharmaceuticals Stock Crawled Higher Today
A solid earnings beat drove the company's share price upward.
Here's Why Vanda Pharmaceuticals Jumped Higher Today
The biotech's sleep drug Hetlioz gained an expanded approval.
1 Pharma Stock to Avoid at All Costs
No matter how much courage an investor has, investing in cheap stocks that have pending whistleblower lawsuits against them just isn't a good idea.
This Under-the-Radar Drug Developer May Have an Answer for Patients With Severe COVID-19
Third-quarter results from a COVID-19 trial could send this stock soaring.
Vanda Pharmaceuticals Returns to Profitability in Q2
The stock popped after the company reported a solid quarter of operations, but serious red flags remain.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.